ClinicalTrials.gg
Not yet recruitingNCT07951060EXUROCUpdated Nov 20, 2026

LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency

A Phase 1/2 interventional study of Intravenous infusion of LP-184 on Day 1 and Day 8 of a 21-day cycle. in Advanced Urothelial Carcinoma, Urothelial Carcinoma (UC) and Urothelial Cancer of Renal Pelvis, sponsored by Kristoffer Rohrberg. Not yet recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Kristoffer Rohrberg · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Carcinoma, Transitional Cell with a site in Denmark — 3 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Transitional Cell · Denmark.

Planned enrollment
13th of 18
39 · median 73
Started
2026
with 1 other
Phase 1/2
3 of 18
1 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Kristoffer Rohrberg

Among the 18 studies in Carcinoma, Transitional Cell with a site in Denmark, this one is the 13th largest by planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 1/2, and was the 18th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

3 of the 18 studies in Carcinoma, Transitional Cell with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Transitional Cell with a site in Denmark, or all of them as a file.
02

Study summary

This study investigates the safety and potential antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma.

LP-184 is an investigational anticancer drug designed to damage the DNA of cancer cells. Certain cancer cells may be particularly sensitive to LP-184 if they have impaired DNA repair mechanisms and express a protein called PTGR1, which is involved in activating the drug.

The study aims to investigate whether LP-184 can be safely administered and whether it can reduce tumor growth in patients whose tumors have these specific characteristics.

The study consists of two parts. Phase Ib will evaluate the safety and tolerability of LP-184 and determine the recommended dose for Phase II. Phase II will investigate the antitumor activity of LP-184 by assessing tumor response to treatment.

All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. Up to 39 patients will be enrolled in the study.

Read the detailed description

EXUROC Bladder Target is an investigator-initiated, single-center, open-label, single-arm Phase Ib/II clinical trial evaluating the safety, tolerability, and antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma (UC) selected by PTGR1 positivity and DNA damage repair (DDR) deficiency.

LP-184 is a next-generation semisynthetic acylfulvene that acts as a prodrug requiring intracellular activation by prostaglandin reductase 1 (PTGR1). Following activation, LP-184 induces DNA damage that may be particularly cytotoxic to tumor cells with deficiencies in DNA repair pathways, including nucleotide excision repair (NER) and homologous recombination (HR). Preclinical studies have demonstrated enhanced sensitivity to acylfulvenes in tumors with impaired DNA repair mechanisms, providing the rationale for biomarker-based patient selection.

The study consists of two sequential phases:

Phase Ib: The first part will evaluate the safety and tolerability of LP-184 and determine the recommended Phase II dose (RP2D). A modified 3+3 dose de-escalation design will be applied, starting at 0.39 mg/kg, with predefined lower dose levels of 0.31 mg/kg and 0.25 mg/kg if dose-limiting toxicities (DLTs) occur. Safety and tolerability will be assessed, and dose de-escalation decisions will be based on observed toxicities.

Phase II: The second part will evaluate the antitumor activity of LP-184 at the RP2D using a Simon's two-stage minimax design. A total of 27 patients will contribute to the Phase II evaluation, including eligible patients treated during Phase Ib. The design allows for early termination if insufficient antitumor activity is observed during the first stage.

LP-184 will be administered intravenously on days 1 and 8 of each 21-day cycle. Treatment may continue for up to one year unless disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria occur.

Tumor response will be evaluated using RECIST version 1.1, and treatment-related adverse events will be assessed using CTCAE version 5.0. Quality of life will be assessed using the EORTC QLQ-C30 questionnaire.

The study aims to determine whether selecting patients based on PTGR1 expression and DDR deficiency can identify a population that may benefit from LP-184 treatment, potentially supporting further clinical development of this biomarker-driven therapeutic strategy.

03

Conditions studied

  • Advanced Urothelial Carcinoma
  • Urothelial Carcinoma (UC)
  • Urothelial Cancer of Renal Pelvis
  • Urothelial Carcinoma Bladder
  • Urothelial Carcinoma Ureter
  • Urothelial Carcinoma Urethra
  • Urothelial Carcinoma of the Renal Pelvis and Ureter
  • Urothelial Carcinoma of the Urinary Bladder
  • Urothelial/Bladder Cancer, Nos

Keywords

  • Urothelial carcinoma
  • LP-184
  • Urinary bladder cancer
  • Urothelial cancer
  • Renal pelvis cancer
  • Ureter cancer
  • Urethra cancer
  • DNA Damage Repair (DDR) deficiency
  • RECIST 1.1
  • EORTC QLQ-C30
  • Hydroxyurea methylacylfulvene
  • Safety
  • Tolerability
  • Efficacy
  • Acylfuvene
  • PTGR1
  • NER deficiency
  • Phase II
  • Phase Ib
  • dosedeescalation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling, and analyses.
  • confirmed progressive, advanced (T4b, N+ or M1) urothelial carcinoma (UC)
  • by 1.1
  • DDR deficiency by local test
  • PTGR1 overexpression as defined by local test
  • performance status 0-1
  • Minimum age of 18 years
  • > 3 months
  • No prior treatment with acylfulvenes
  • At least one . Patients ineligible for standard second-line treatment may be considered for inclusion.
  • At least 4 weeks after major surgery or radiotherapy. Short-duration, limited-field radiotherapy for symptom control is allowed until 2 weeks before C1D1.
  • Adequate organ function at screening defined as:
  • Liver Function:

*, ALT* ≤3 × or \<5 × ULN in cases of documented liver or involvement of the liver in the disease process.

Total serum * ≤1.5 × ULN or \<5 × ULN if secondary to Gilbert's Syndrome or documented liver metastases or involvement of the liver in the disease process.

•Renal Function: Serum ≥45 mL/min either measured or calcu-lated using the standard Cockcroft-Gault formula.

•Bone Marrow Function:ANC* ≥1,5 × 10⁹/L. * ≥5,0 mmol/L (The use of transfusion or other interven-tion to achieve hemoglobin ≥5,0 mmol/L is acceptable. For those pa-tients undergoing RBC transfusion, hemoglobin must be evaluated at least 14 days after the last RBC transfusion).

count* ≥100 × 10⁹/L (assessed ≥7 days following last platelet transfusion in patients with thrombocytopenia requiring platelets).

•Blood clotting function: * and aPTT* ≤1.5 × ULN. Patients on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for the intended use.

Women of (WOCBP) must have a negative serum pregnancy test within 3 days of the first dose of LP-184. A woman is of child bearing potential unless she:

  • has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy.
  • is aged ≥60 years and is amenorrhoeic.
  • is aged \<60 years and has been amenorrhoeic for ≥12 months (including no irregular menses or spotting) in the absence of any medication which induces a meno-pausal state and has documented ovarian failure by serum estradiol and follicle-stimulating hormone.

Women of childbearing potential must use highly effective . Men of must agree to use highly effective contraceptive methods and avoid sperm donation during the study treatment and for 3 months after the last dose of LP-184. A man is of reproductive potential unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.

Regarding , based on one of the following:

  • No clinical evidence of brain metastases.
  • Previously treated brain metastases that are either stable for at least 4 weeks since last treatment or progressed since prior local CNS therapy and not requiring imme-diate re-treatment with local therapy.
  • Patients on a chronic stable dose of ≤2 mg total daily of dexamethasone (or equivalent) are eligible.

Exclusion criteria

Exclusion Criteria:

  • Exposure to anti-cancer therapy within 2 weeks or within at least 5 half-lives of the anti-cancer agent whichever is shorter; or 4 weeks from any biologics/immunotherapies or any therapy prior to the first dose of LP-184. (Note: low-dose (oral prednisone or equivalent ≤20 mg/day), localized non-CNS radiotherapy, previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer, and treatment with bisphosphonates and RANKL inhibitors are not criteria for exclusion if such therapy has not been changed within 4 weeks before LP-184 treatment.)
  • Any history of retinopathy and/or macular degeneration (without specifications or grades).
  • Infection requiring antibiotics, antivirals, or antifungals within 1 week prior to first dose of study drug. Prophylactic therapy for e.g. urinary tract infections allowed.
  • and/or infection (determined on baseline hepatitis B and C screen) or known seropositivity for or history of active viral infection with (HIV).
  • Have cardiac disease including:

    • Class IV heart failure.
    • Myocardial infarction or stroke ≤3 months prior to the first dose of LP-184.
    • Unstable angina within ≤12 weeks prior to the first dose of LP-184 unless the underlying disease has been corrected by procedural intervention e.g., stent, bypass.
    • Severe aortic stenosis.
    • Uncontrolled arrhythmia.
    • >470 milliseconds by Fridericia criteria.
    • Congenital long QT syndrome, or a QTcF interval >470 ms (average of triplicate ECGs) at screening and on Cycle 1 Day 1 (pre-dose) except for a documented bundle branch block or unless secondary to a pacemaker.
  • Have clinically significant AEs that have not resolved to baseline or ≤Grade 1 based on prior to first dose of study drug, unless approved by the sponsor. Patients with chronic Grade 2 toxicities may be eligible at the discretion of the investigator, e.g. Grade 2 chemotherapy-induced neuropathy, alopecia, or hypothy-roidism from prior immunotherapy treatment).
  • Have any other serious medical condition which, in the opinion of the investigator, would preclude the patient from study participation.
  • Pregnant or breastfeeding women, or women of unwilling or unable to comply with requirements.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    LP-184 arm

    All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. In Phase Ib, a modified 3+3 dose de-escalation design will be used to determine the recommended Phase II dose (RP2D). In Phase II, participants will receive LP-184 at the established RP2D.

    Drug: Intravenous infusion of LP-184 on Day 1 and Day 8 of a 21-day cycle.

Interventions

  • DrugIntravenous infusion of LP-184 on Day 1 and Day 8 of a 21-day cycle.

    LP-184 is an investigational semisynthetic acylfulvene administered intravenously on days 1 and 8 of each 21-day cycle. In Phase Ib, the starting dose is 0.39 mg/kg, with predefined dose de-escalation levels of 0.31 mg/kg and 0.25 mg/kg. In Phase II, LP-184 will be administered at the recommended Phase II dose (RP2D) established during Phase Ib. Treatment may continue for up to one year or until disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity

    Number and proportion of participants experiencing dose-limiting toxicities (DLTs) associated with LP-184 treatment, assessed according to the protocol-defined DLT criteria and graded using CTCAE version 5.0.

    Time frame: During the first treatment cycle (21 days).

  2. Recommended Phase II Dose (RP2D) of LP-184

    Determination of the recommended Phase II dose (RP2D) of LP-184 based on observed dose-limiting toxicities and overall safety and tolerability during Phase Ib.

    Time frame: During Phase Ib dose evaluation, up to approximately 6 months

  3. Objective Response Rate (ORR) According to RECIST Version 1.1

    Proportion of participants achieving a complete response (CR) or partial response (PR) as their best overall response, assessed according to RECIST version 1.1.

    Time frame: From treatment initiation until disease progression or end of treatment, up to 1 year.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time from initiation of LP-184 treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: From initiation of LP-184 treatment until the first documented disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

  2. Overall Survival (OS)

    Time from initiation of LP-184 treatment to death from any cause.

    Time frame: From initiation of LP-184 treatment until death from any cause or last follow-up, assessed up to approximately 18 months.

  3. Duration of Response (DoR)

    Time from the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, among participants achieving an objective response according to RECIST version 1.1.

    Time frame: From the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

07

Study locations

1 site
  • Rigshospitalet, Phase 1 Unit, Department of Oncology, Section 5073. Address: Blegdamsvej 9, 2100 Copenhagen, Denmark
    Copenhagen, 2100, Denmark
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not currently planned to be shared with external researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.

Of 47 phase 1/2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 224. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 20, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2031
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951060
Lead sponsor
Kristoffer Rohrberg
Responsible party
Kristoffer Rohrberg (MD, PhD, Assistant Professor, Sponsor-Investigator, Copenhagen University Hospital, Rigshospitalet) — Sponsor-investigator
First posted
Nov 20, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Nov 2029 (estimated)
Completion
Nov 2031 (estimated)
Last update
Nov 20, 2026

Study contacts

Kristoffer S. Rohrberg, MD, PhD
Contact
kristoffer.staal.rohrberg@regionh.dk
+45 35 45 63 53
Helle Pappot, MD, DMSc
Contact
Helle.Pappot@regionh.dk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion